Carvolix S.A.
CVX.PA
Get informed when a big investor buys or sells
+ FollowMarket Cap$211.22M
Close$
$-0.57
110.9% downside
Current Fair Value
110.9% downsideOvervalued by 110.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $211.22 Million |
|---|---|
| Enterprise Value | $230.14 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.63 |
| Beta | 1 |
| Outstanding Shares | 55,527,082 |
Return
| Return on Equity | -102.01% |
|---|---|
| Return on Assets | -44.36% |
| Return on Invested Capital | -58.27% |
Valuation & Multiples
| P/E Ratio | -8.28 |
|---|---|
| PEG | -17.2 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 49.02 |
| Enterprise Value to EBIT | -5.76 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.45 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 30, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
April 29, 2027
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Carvolix S.A.
104 employees
CEO: Sebastien Ladet Carvolix S.A. operates as a medical technology firm, concurrently involved in both commercialization and clinical development, specializing in treatment solutions for structural heart ailments and cerebral strokes. The company's innovati...